In view of the widespread dysregulated expression of the Wnt-regulated signaling molecules in NPC, we hypothesized that selective pharmacological intervention at the distal end of the Wnt/β-catenin signaling pathway, namely the interaction between β-catenin and the co-activator CBP by the CBP antagonist ICG-001 [19,20], might be a novel strategy to control the growth and migration of NPC cells. This evidence concerns the gene CREBBP and nasopharyngeal carcinoma.